Innovation, Safety and Experience

Learn more about Farmalíder Group

Who we are

Grupo Farmalíder is a Spanish-owned pharmaceutical company founded in 1986, dedicated to the research, development and manufacture of pharmaceutical specialties. Our headquarters are located in Alcobendas (Madrid) and we have offices in Barcelona (Spain) and Miami (USA). In addition, we have two manufacturing plants of our own. They are located in Alcobendas (Madrid) and Valencia (Spain).

What we offer

At Farmalíder we provide a specialized service to pharmaceutical laboratories or companies related to this sector, offering licensing for specialized products with limited competition, products with unique presentations and innovative products and/or associations, as well as other products protected by patents.

How we do it

We have two production plants, which, in compliance with GMP regulations, allow us to develop and scale up formulations, being able to manufacture batches for clinical trials and registration documentation. In this way, we can offer our customers all the work from the idea to the delivery of the finished product and its subsequent collaboration in the marketing processes.

The Farmalíder Group has

Two of our own manufacturing plants

Villamarxant (Valencia)

Manufacture and packaging of pharmaceutical products (liquids/granulates) and food supplements.

Alcobendas (Madrid)

Manufacturing and packaging of pharmaceutical products specialized in solid oral forms.

Who we are

Farmalíder is a team of professionals, doctors and senior technicians, experts in drug development and registration, as well as pharmacologists specialized in clinical trial design. Thanks to our experience, at Farmalíder we patent our knowledge, proactively registering dossiers to offer our clients immediate commercialization opportunities. Through Nutra Essential OTC, one of the group's companies, we manage the development of OTC products, medicines, nutritional supplements and dermocosmetics, collaborating with companies worldwide.

Our Goals

Our development plan currently includes ongoing projects at different stages of development, some in their initial preformulation phase and others in their final phase of clinical trials, all of them with added value, whether for new product indications, new combinations or new dosage forms. Although we have approved and marketed products and projects under development aimed at various therapeutic areas, currently 65% of the developments are focused on pain treatment. These developments are being carried out in different dosage forms that can be easily administered by different routes, parenterally and orally. Likewise, at Farmalíder we are always looking to provide a galenic innovation to the products to simplify the administration of medicines and improve the life of patients, such as the orodispersible products, which avoid the need to swallow a whole dosage unit and even allow to dispense with taking them with water. For all these reasons, Farmalíder is defined as a Factory of Ideas.

Our achievements

These are some of our most recent achievements:

  • Leader in the Spanish Ibuprofen supply market.
  • 2001 patented ibuprofen 4% oral suspension in bottle. Patented license in 17 countries.
  • Authorization in Germany for the marketing of Ibuprofen 2% and 4%, in the form of oral suspension in bottle, through the decentralized procedure (DCP).
  • Creation of the company Nutra Essential OTC, in charge of all OTC products and nutritional supplements of the Farmalíder Group.
  • Creation of Vitalcare, in cooperation with ERN Laboratories, for the manufacture of pediatric and women's health products.
  • 2011 Farmalider acquired TOLLPHARMA, a wholly owned European GMPS factory.
1 º
First to develop and license Paracetamol 1g tablets in the European market.
+ 0
Marketing authorizations available in the European Union.
+ 0
R&D Projects
+ 0
e-CTD updated dossiers